|
Orthologous residues
|
|
HTRA2 (human): S400‑p, HTRA2 iso2 (human): ‑, HTRA2 (mouse): S400‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
neuroblastoma
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), SH-SY5Y (neural crest)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
CDK5 (human)
|
genetic knockout/knockin of upstream enzyme, co-immunoprecipitation, phospho-antibody, pharmacological inhibitor of upstream enzyme, microscopy-colocalization, modification site within consensus motif, pharmacological activator of upstream enzyme, siRNA inhibition of enzyme
|
|
|
|
Comments:
S142 is required for maximal phosphorylation of S400.
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
|
|
p38-alpha (human)
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Comments:
S400 phosphorylation is important for mitochondrial function.
|